Half-Year 2022 Financial and Clinical Trials Update

Xolair Humanized monoclonal antibody that selectively binds to IgE Indication Food allergy Phase/study Phase III OUTMATCH¹ # of patients N=225 • Xolair by SC injection either q2w or q4w for 16 to 20 weeks Design Primary endpoint • Number of participants who successfully consume ≥600mg of peanut protein without dose-limiting symptoms Status • ⚫ FPI Q3 2019 CT Identifier In collaboration with Novartis; 1 Sponsor of the study is the National Institute of Allergy and Infectious Diseases (NIAID) IgE-Immunoglobulin E; SC-Subcutaneous NCT03881696 117 Roche Immunology

View entire presentation